Free shipping on all orders over $ 500

LDE225

Cat. No. M2338

All AbMole products are for research use only, cannot be used for human consumption.

LDE225 Structure
Synonym:

Sonidegib; NVP-LDE225; Erismodegib

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
2mg USD 40  USD40 In stock
5mg USD 60  USD60 In stock
10mg USD 85  USD85 In stock
25mg USD 150  USD150 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

LDE225 (NVP-LDE225, also known as Sonidegib or erismodegib) is a potent and selective Hedgehog signaling pathway inhibitor (Smoothened antagonist) reduces melanoma growth in vitro and in vivo. NVP-LDE225 was potent in reducing cell proliferation and inducing tumor growth arrest in vitro and in vivo, respectively. Pharmacologic inhibition of BRAF(V600E) in human melanoma cell lines resulted in decreased expression of GLI1 thus demonstrating interaction of SHH-GLI and MAPK pathways. Inhibition of SHH-GLI pathway by the novel small molecule inhibitor of smoothened NVP-LDE225 was followed by inhibition of cell growth and induction of apoptosis in human melanoma cell lines, interestingly with both BRAF(V600E) and BRAF(Wild Type) status.

Product Citations
Customer Product Validations & Biological Datas
Source BMC Cancer (2017). Figure 4. LDE225
Method western blot
Cell Lines BALB/c nude mice
Concentrations 80 mg/kg
Incubation Time 41 day
Results Western blotting showed increased amounts of GLI1 in tumors from animals treated with 177Lu-octreotate monotherapy and combination treatment, and increased amounts of GLI2 in tumors from the combination therapy group, compared with controls
Chemical Information
Molecular Weight 485.5
Formula C26H26F3N3O3
CAS Number 956697-53-3
Solubility (25°C) DMSO 60 mg/mL
Ethanol 50 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Jalili A, et al. PLoS One. NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo.

[2] Fendrich V, et al. Ann Surg. Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms.

Related Hedgehog Products
Cyclopamine

Cyclopamine is a naturally occuring steroidal alkaloid that causes cyclopia by blocking sonic hedgehog signaling.

LY2940680

LY2940680 is a potent Hedgehog inhibitor with potential anticancer activity.

PF-5274857

PF-5274857 is a novel Smoothened antagonist, inhibits Hedgehog signaling with IC50 and Ki values of 5.8 nM and 4.6 nM, respectively.

Jervine

Jervine is a naturally occuring steroidal alkaloid that causes cyclopia by blocking sonic hedgehog signaling.

Ciliobrevin A

Ciliobrevin A (HPI-4) is a hedgehog (Hh) pathway antagonist. It blocks Sonic hedgehog (Shh)-induced Hh pathway activation (IC50 = 7 μM) downstream of Smo.

  Catalog
Abmole Inhibitor Catalog




Keywords: LDE225, Sonidegib; NVP-LDE225; Erismodegib supplier, Hedgehog, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.